In the rush to develop a vaccine or treatment for Covid-19, drug companies are fast-tracking clinical trials. But those trials have a major diversity problem. Participants in major drug trials range from 70 percent to 89 percent white. This is a big problem, considering it’s a disease that disproportionately affects people of color. Kristen V. Brown reports that failing to account for minority groups could potentially impact how well a drug eventually works for those that the virus has harmed the most.

In the rush to develop a vaccine or treatment for Covid-19, drug companies are fast-tracking clinical trials. But those trials have a major diversity problem. Participants in major drug trials range from 70 percent to 89 percent white. This is a big problem, considering it’s a disease that disproportionately affects people of color. Kristen V. Brown reports that failing to account for minority groups could potentially impact how well a drug eventually works for those that the virus has harmed the most.

Reality TV stars are freezing their eggs on camera. Lawmakers in DC are debating federal protection for IVF. Hundreds of millions of dollars are being invested in slick startups that market fertility treatments for all. But this rapid growth has revealed cracks in the system. Misconception, a new series from Bloomberg’s Prognosis, follows reporter Kristen V. Brown on her own intimate journey as she uncovers the business of fertility. Along the way, she finds a fractured industry — a profit-driven field of medicine that thrives on dueling messages of hope and fear as people gamble everything for a chance at a baby.

Reality TV stars are freezing their eggs on camera. Lawmakers in DC are debating federal protection for IVF. Hundreds of millions of dollars are being invested in slick startups that market fertility treatments for all. But this rapid growth has revealed cracks in the system. Misconception, a new series from Bloomberg’s Prognosis, follows reporter Kristen V. Brown on her own intimate journey as she uncovers the business of fertility. Along the way, she finds a fractured industry — a profit-driven field of medicine that thrives on dueling messages of hope and fear as people gamble everything for a chance at a baby.

Prognosis: Misconception

For much of human history, we’ve turned to diets to lose weight and improve our health. But it’s mostly been in vain. No matter how much the number on the scale drops begins to go down, chances are that the weight will come back. That’s just what the science says. But when it comes to weight, the facts just don’t seem to matter. Losing It, a new series from Bloomberg’s Prognosis, looks at how we got weight loss so wrong — and whether there’s a better way forward.

For much of human history, we’ve turned to diets to lose weight and improve our health. But it’s mostly been in vain. No matter how much the number on the scale drops begins to go down, chances are that the weight will come back. That’s just what the science says. But when it comes to weight, the facts just don’t seem to matter. Losing It, a new series from Bloomberg’s Prognosis, looks at how we got weight loss so wrong — and whether there’s a better way forward.

The Race Gap in Clinical Trials

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/d9a12625-f8e5-400e-88d3-ae390091bef4/transcript